



RESVERLOGIX (TSX:RVX) IS A LATE-STAGE BIOTECH COMPANY WITH A NOVEL EPIGENETIC APPROACH TO REDUCING THE INCIDENCE OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN HIGH-RISK PATIENTS. LEAD DRUG APABETALONE CURRENTLY IN A PHASE 3 CLINICAL TRIAL CALLED BETONMACE.

Resverlogix is bringing safe, affordable, first-in-class epigenetic therapeutics to people with heart disease, diabetes, chronic kidney disease and other life-threatening illnesses. Our lead drug candidate **apabetalone** is currently in a **Phase 3 clinical trial, BETonMACE**, which will be fully enrolled in the first half of 2018.



MULTI-MODAL PATHWAY MECHANISM


Apabetalone, a bromodomain extra-terminal (BET) protein inhibitor regulates the expression of genes and restores the function of pathways underlying the pathogenesis of **cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease**.



✉ : ir@resverlogix.com
 ☎ : 403.254.9252
 🌐 : www.resverlogix.com
 🐦 : @Resverlogix_RVX




TSX:
RVX



Epigenetics

While most people are familiar with the inheritance of genes via DNA from one generation to the next, the activity of these genes is actually determined by epigenetics, which literally means “on top of” genetics. DNA is considered the hardware of the human body, while epigenetics can be referred to as the software. DNA contains the code that tells our cells what to do, and this coded message is the same in every cell and does not change with time. However, our cells do not behave in the exact same way across time, particularly when disease is involved. Epigenetic changes to the DNA allow the message in the genes to be turned up or down like a dimmer switch, telling the cells which products to make more, or less of. During this process the DNA is not altered. The epigenetic control over the genetic message in the DNA underlies many diseases, and for this reason, epigenetics has become an exciting forefront for the discovery of new medicines.

APABETALONE (RVX-208) CLINICAL TRIAL HISTORY



- Phase 3 BETonMACE trial commenced Q4/15 for high-risk CVD patients with type 2 diabetes mellitus and low HDL. ~15% of the patients will also have CKD. BETonMACE is currently 95% enrolled.
- Primary endpoint: time to first occurrence of Major Adverse Cardiac Events (MACE).
- Based on mechanistic data, we believe apabetalone treatment, or select BET inhibition, attenuates the inflammatory process that contributes to disease initiation and progression.
- We hypothesize that apabetalone treatment modulates activity of the inflammatory and innate immune responses, as well as the coagulation cascade with immediate benefits to atherosclerosis and CVD.

Recent News

Feb. 26: RVX announced the independent Data and Safety Monitoring Board (DSMB) for Phase 3 BETonMACE trial in CVD patients completed a 6th safety review and recommended the study should continue as planned.

March Events

- ACC.18, Orlando, March 10-12
- BIO Europe Spring, Amsterdam, March 12-14
- AAT-AD/PD, Torino, March 15-18

Analyst & Media

- 16 JAN 18 - Van Leeuwenhoek Research: Debt Removal Reduces Risk Profile - Marcel Wijma, MSc
- 15 NOV 17 - Beacon Securities: The New Doctor Is In. First Prescription Is A Full Dose of Resverlogix: C\$8.55 - David M. Kideckel, PhD, MBA.
- 02 AUG 17 - Zacks Analyst Report: Cash Crunch; BETonMACE Continues Unaffected. Financing Expected Soon - John Vandermosten, CFA.

Financial Profile

- Shares O/S* (MM): 175.0
- Share Price*: \$1.77
- Market Cap* (MM): ~\$297.6
- 52 week low/high*: \$1.23/\$2.47
- Cash Balance** (MM): ~\$0.7
- Cash Burn Rate** (MM): ~\$3.1/mo.
- Total Cash Raised* (MM): ~\$397

Notes: *As at 07-MAR-18, **As at 31-OCT-17